Literature DB >> 29046142

The Roles of microRNAs in Regulating Chemotherapy Resistance of Non-Small Cell Lung Cancer.

Xiaoxuan Wei1,2, Xiaoyan Shen1,2, Yanchen Ren1,2, Weidong Hu1,2.   

Abstract

Lung cancer is considered the leading cause of cancer death in the word. Among all lung cancer cases, non-small cell lung cancer (NSCLC) accounts for 85%. Currently, chemotherapy is still the major therapeutic method of lung cancer. However, chemoresistance is a serious obstacle in treating NSCLC. Up to now, many reports have suggested that microRNAs(miRNAs) could contribute to lung cancer cell chemosensitivity. MicroRNAs, a class of endogenous non-coding small RNAs, regulate gene expression by binding to their complementary target messenger RNAs, leading to mRNA degradation or translational suppression. Numerous studies indicate that changes of specific miRNA expression may contribute to chemoresistance or chemosensitivity. Consequently, targeting specific miRNAs could become an effective approach to predict the therapeutic effect of different anticancer agents, achieve more effective personalised treatments and enhance chemosensitivity. This review summarizes the several major drug resistance mechanisms and focuses on the roles of miRNAs in regulating chemoresistance in NSCLC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  MicroRNAs; chemosensitivity; chemotherapy; cisplatin; drug resistance; non-small cell lung cancer (NSCLC)

Mesh:

Substances:

Year:  2018        PMID: 29046142     DOI: 10.2174/1381612823666171018105207

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.

Authors:  Changyu Zhu; Xiaolei Jiang; Hua Xiao; Jianmei Guan
Journal:  Biochem Genet       Date:  2022-04-23       Impact factor: 1.890

2.  APE1 controls DICER1 expression in NSCLC through miR-33a and miR-130b.

Authors:  Giulia Antoniali; Emiliano Dalla; Giovanna Mangiapane; Xiaolong Zhao; Xinming Jing; Yi Cheng; Veronica De Sanctis; Dilara Ayyildiz; Silvano Piazza; Mengxia Li; Gianluca Tell
Journal:  Cell Mol Life Sci       Date:  2022-07-25       Impact factor: 9.207

3.  Circ_0001821 knockdown suppresses growth, metastasis, and TAX resistance of non-small-cell lung cancer cells by regulating the miR-526b-5p/GRK5 axis.

Authors:  Ying Liu; Changchao Li; Huiqun Liu; Jing Wang
Journal:  Pharmacol Res Perspect       Date:  2021-08

4.  miR-486 as an unfavorable prognostic biomarker for patients with non-small cell lung cancer.

Authors:  Zhao-Jia Gao; Wei-Dong Yuan; Jun-Qiang Yuan; Kai Yuan; Yong Wang
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

5.  MicroRNA-326 impairs chemotherapy resistance in non small cell lung cancer by suppressing histone deacetylase SIRT1-mediated HIF1α and elevating VEGFA.

Authors:  Jinying Wei; Guangping Meng; Jing Wu; Ying Wang; Qiang Zhang; Ting Dong; Jin Bao; Chunyan Wang; Jie Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.